CHO / HEK platforms
Specialized in CHO and HEK expression for monoclonal antibodies and recombinant proteins, using both stable and transient systems to balance speed, risk, and long-term supply.
About ArtProtein
ArtProtein is a biologics CDMO focused on helping small and mid-size biotech teams progress complex antibody and recombinant protein programs in CHO and HEK systems.
Our focus
Process & scale-up
Development from scale-down models to process-controlled bioreactors, with an emphasis on designs that transfer cleanly into GMP manufacturing environments.
CMC & USDA 9CFR support
Technical documentation, development summaries, and USDA 9CFR–aligned proposals, study plans, and reports to support clear communication with regulators and partners.
Experience
20+ years in biologics
ArtProtein is led by professionals with more than two decades of experience in biologics R&D and large-scale protein production across multiple platforms and indications.
Cell line & process development
Extensive work in CHO/HEK cell line development, transient and stable expression, upstream optimization, and purification concepts for difficult-to-express molecules.
Regulatory and CMC
Hands-on experience preparing CMC content, development reports, and USDA 9CFR–driven documentation for global regulatory and internal governance needs.
How we work
Molecule-first approach
We start from your molecule, current data, and constraints, then identify the decisions that will matter most for cost, risk, and timeline.
Actionable deliverables
You receive clear study designs, development roadmaps, and documentation that can be used internally, with ArtProtein, and with external partners and regulators.
Long-term partnership
Our goal is to be a technical partner over the life of your program, not just a one-project vendor, with honest communication about risks and tradeoffs.